Veralto Free cash flow decreased by 41.6% to $170.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $142.00M to $170.00M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 6.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $210.50M | $210.50M | $210.50M | $329.00M | $147.00M | $289.00M | $232.00M | $241.00M | $102.00M | $240.00M | $215.00M | $263.00M | $142.00M | $323.00M | $258.00M | $291.00M | $170.00M |
| QoQ Change | — | +0.0% | +0.0% | +56.3% | -55.3% | +96.6% | -19.7% | +3.9% | -57.7% | +135.3% | -10.4% | +22.3% | -46.0% | +127.5% | -20.1% | +12.8% | -41.6% |
| YoY Change | — | — | — | +56.3% | — | — | — | -26.7% | -30.6% | -17.0% | -7.3% | +9.1% | +39.2% | +34.6% | +20.0% | +10.6% | +19.7% |